Citius Pharmaceuticals Secures Funding for LYMPHIR™ Cancer Immunotherapy Launch

Citius Oncology Secures Funding for LYMPHIR™ Launch

Citius Oncology, Inc., a subsidiary of Citius Pharmaceuticals, Inc., announces a significant strategic move that aims to strengthen its financial foundation in preparation for the anticipated commercial launch of its innovative cancer immunotherapy, LYMPHIR™. This product, specifically developed for treating cutaneous T-cell lymphoma (CTCL), represents a pivotal advancement in oncology therapeutics. The company enters into a definitive agreement with a healthcare-focused investor to sell 1,284,404 shares of common stock at a price of $1.09 per share through a registered direct offering. In conjunction with this, the investor will receive unregistered warrants allowing for the purchase of an equivalent number of shares, contingent upon stockholder approval.

In addition to the registered direct offering, Citius Oncology secures a private placement for 15,229,358 shares and corresponding warrants at the same price of $1.09 per share. H.C. Wainwright & Co. is acting as the exclusive placement agent for these financial transactions, which together are projected to generate approximately $18 million in gross proceeds before fees and expenses. The anticipated closing date for these transactions is on or about December 10, 2025, pending standard closing conditions. This funding initiative not only underscores Citius Oncology's dedication to enhancing its product pipeline but also reinforces its operational capabilities within the competitive oncology landscape.

The proceeds from these offerings are earmarked for the commercial launch of LYMPHIR™ and will also support general corporate purposes and working capital. With a focus on addressing unmet medical needs in cancer treatment, Citius Oncology demonstrates its commitment to advancing innovative therapies that can significantly improve patient outcomes. The strategic financial maneuver highlights the company’s proactive approach to ensuring that it has the necessary resources to execute its vision in the oncology sector effectively.

Citius Oncology's efforts in securing this funding reflect a growing trend within the biopharmaceutical industry where companies prioritize financial stability to facilitate the introduction of new treatments. As LYMPHIR™ progresses towards market availability, Citius positions itself as a key player in the oncology field, ready to make a meaningful impact on patients suffering from CTCL and other related conditions.